Retrospective evaluation of the effectiveness of epsilon aminocaproic acid for the prevention of postamputation bleeding in retired racing Greyhounds with appendicular bone tumors: 46 cases (2003-2008)

Journal of Veterinary Emergency and Critical Care

Volumn 22, Issue 3, 2012, Pages 332-340

  Marín, Liliana M ^a   Iazbik, M Cristina ^a   Zaldivar Lopez, Sara ^a   Lord, Linda K ^a   Stingle, Nicole ^a   Vilar, Paulo ^a,c   Lara Garcia, Ana ^a,d   Alvarez, Francisco ^a,e   Hosoya, Kenji ^a,f   Nelson, Laura ^a,c   Pozzi, Antonio ^a,g   Cooper, Edward ^a   Mcloughlin, Mary A ^a   Ball, Rebecca ^a,h   Kisseberth, William C ^a,b   London, Cheryl A ^a,b   Dudley, Robert ^a,i   Dyce, Jonathan ^a   Mcmahon, Melanie ^a,j   Lerche, Phillip ^a   Bednarski, Richard ^a   Couto, C Guillermo ^a,b   more..

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d ROYAL VETERINARY COLLEGE   (United Kingdom)

^e Hokkaido University ^*  (United States)

^f HOKKAIDO UNIVERSITY   (Japan)

^g UNIVERSITY OF FLORIDA   (United States)

^h Indianapolis Veterinary Referral   (United States)

ⁱ MedVet Medical and Cancer Center for Pets   (United States)

^j VCA Shoreline Veterinary Referral Emergency Center   (United States)

more..

Author keywords

Coagulation; Dog; Osteosarcoma; Postoperative complications

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT;

AMPUTATION; ANIMAL; ANIMAL DISEASE; ARTICLE; BLEEDING; BONE TUMOR; DOG; DOG DISEASE; GENETIC PREDISPOSITION; GENETICS; OSTEOSARCOMA; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY;

6-AMINOCAPROIC ACID; AMPUTATION; ANIMALS; ANTIFIBRINOLYTIC AGENTS; BONE NEOPLASMS; DOG DISEASES; DOGS; GENETIC PREDISPOSITION TO DISEASE; HEMORRHAGE; OSTEOSARCOMA; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES;

ANIMALIA; CANIS FAMILIARIS;

EID: 84862697924     PISSN: 14793261     EISSN: 14764431     Source Type: Journal    
DOI: 10.1111/j.1476-4431.2012.00735.x     Document Type: Article

References (56)

1. Neuhaus D, Fedde MR, Gaehtgens P. Changes in hemorheology in the racing Greyhound as related to oxygen delivery. Eur J Appl Physiol 1992;65:278-285.
2. Steiss J, Brewer W, Welles E, et al. Hematologic and serum biochemical reference values in retired Greyhounds. Comp Cont Educ Pract 2000;22:243-248.
3. Couto CG, Lara A, Iazbik MC, et al. Evaluation of platelet aggregation using a point-of-care instrument in retired racing Greyhounds. J Vet Intern Med 2006;20:365-370.
4. Campora C, Freeman KP, Lewis FI, et al. Determination of haematological reference intervals in healthy adult Greyhounds. J Small Anim Pract 2011;52:301-309.
5. Fayos M, Couto CG, Iazbik MC, et al. Serum protein electrophoresis in retired racing Greyhounds. Vet Clin Path 2005;34:397-400.
6. Couto C, Cerón J, Parra M, et al. Acute phase protein concentrations in retired racing Greyhounds. Vet Clin Pathol 2009;38:219-223.
7. Gaughan K, Bruyette D. Thyroid function testing in Greyhounds. Am J Vet Res 2001;62:1130-1133.
8. Shiel R, Brennan S, Omodo-Eluk A, et al. Thyroid hormone concentrations in young, healthy, pretraining Greyhounds. Vet Rec 2007;161:616-619.
9. Lord LK, Yaissle JE, Marin L, et al. Results of a web-based health survey of retired racing Greyhounds. J Vet Intern Med 2007;21:1243-1250.
10. Straw RC, Powers BE. Management of canine appendicular osteosarcoma. Vet Clin North Am Small Anim Pract 1990;20:1141-1161.
11. Cooley DM, Beranek BC, Schlittler DL, et al. Endogenous gonadal hormone exposure and bone sarcoma risk. Cancer Epidemiol Biomarkers Prev 2002;11:1434-1440.
12. Mueller F, Fuchs B, Kaser-Hotz B. Comparative biology of human and canine osteosarcoma. Anticancer Res 2007;27(1A):155-164.
13. Straw RC, Withrow SJ. Limb-sparing surgery versus amputation for dogs with bone tumors. Vet Clin N Am Small 1996;26:135-143.
14. Liptak JM, Dernell WS, Ehrhart N, et al. Canine appendicular osteosarcoma: curative-intent treatment. Comp Cont Educ Pract 2004;26:186-197.
15. Adams GL, Manson RJ, Turner I, et al. The balance of thrombosis and hemorrhage in surgery. Hematol Oncol Clin N 2007;21:13-24.
16. Kirpensteijn J, Van den Bos R, Endenburg N. Adaptation of dogs to the amputation of a limb and their owners' satisfaction with the procedure. Vet Rec 1999;144:115-118.
17. Knapp DW, Tomlinson JL, Constantinescu GM. Pelvic limb removal by coxo-femoral disarticulation in 13 dogs. J Small Anim Pract 1990;31:561-567.
18. Lara-Garcia A, Couto CG, Iazbik MC, et al. Postoperative bleeding in retired racing Greyhounds. J Vet Intern Med 2008;22:525-533.
19. Berzon JL. Complications of elective ovariohysterectomies in the dog and cat at a teaching institution: clinical review of 853 cases. Vet Surg 1979;8:89-91.
20. Pollari F, Bonnett B, Bamsey S, et al. Postoperative complications of elective surgeries in dogs and cats determined by examining electronic and paper medical records. J Am Vet Med Assoc 1996;208:1882-1886.
21. Burrow R, Batchelor D, Cripps P. Complications observed during and after ovariohysterectomy of 142 bitches at a veterinary teaching hospital. Vet Rec 2005;157:829-833.
22. Marín L CC, Iazbik MC, Lara A, et al. Hemostatic complications after limb amputation in retired racing Greyhounds. In: proceedings of the 25th ACVIM forum, Seattle, WA, 2007, p. 573.
23. Logan JC, Callan MB, Drew K, et al. Clinical indications for use of fresh frozen plasma in dogs: 74 dogs (October through December 1999). J Am Vet Med Assoc 2001;218:1449-1455.
24. Knowler C, Giger U, Dodds WJ, et al. Factor-Xi deficiency in Kerry-Blue terriers. J Am Vet Med Assoc 1994;205:1557-1561.
25. Stokol T, Parry B. Efficacy of fresh-frozen plasma and cryoprecipitate in dogs with von Willebrand's disease or hemophilia A. J Vet Intern Med 1998;12:84-92.
26. Feldman DG, Brooks MB, Dodds WJ. Hemophilia B (factor IX deficiency) in a family of German shepherd dogs. J Am Vet Med Assoc 1995;206:1901-1905.
27. Carpenter SL, Mathew P. Alpha(2)-antiplasmin and its deficiency: fibrinolysis out of balance. Haemophilia 2008;14:1250-1254.
28. Ross J, Dallap BL, Dolente BA, et al. Pharmacokinetics and pharmacodynamics of epsilon-aminocaproic acid in horses. Am J Vet Res 2007;68:1016-1021.
29. Mannucci PM. Hemostatic drugs. N Engl J Med 1998;339:245-253.
30. Okamoto S. Plasmin and antiplasmin. Their pathologic physiology. Keio J Med 1959;8:211-217.
31. Sherry S, Fletcher A, Alkjaerisg N, et al. E-amino-caproic acid. "A potent antifibrinolytic agent." Trans Assoc Am Physicians 1959;72:62-70.
32. Fetter TR, Bowman WD, Cottone RN, et al. Effect of epsilon aminocaproic acid on bleeding after prostatectomy. J Urol 1961;85:970-972.
33. Rueda Gonzalez R. Use of epsilon aminocaproic acid in abnormal hemorrhage using intrauterine contraceptive devices. Rev Colomb Obstet Ginecol 1969;20:273-278.
34. Steiger B, White JG, Krivit W. Epsilon-aminocaproic acid for hematuria in hemophilia. J Lancet 1962;82:421-429.
35. Reid WO, Francisc J, Lucas ON, et al. Use of epsilon-aminocaproic acid in management of dental extractions in hemophiliac. Am J Med Sci 1964;248:184-188.
36. Koster A, Schirmer U. Re-evaluation of the role of antifibrinolytic therapy with lysine analogs during cardiac surgery in the post aprotinin era. Curr Opin Anesthesio 2011;24:92-97.
37. Martin K, Gertler R, Sterner A, et al. Comparison of blood-sparing efficacy of epsilon-aminocaproic acid and tranexamic acid in newborns undergoing cardiac surgery. Thorac Cardiovasc Surg 2011;59:276-280.
38. Berenholtz SM, Pham JC, Garrett-Mayer E, et al. Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal surgery. Spine 2009;34:2096-2103.
39. Roberts I, Shakur H, Ker K, et al. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev 2011;Jan 19;(1):CD004896.
40. Eubanks JD. Antifibrinolytics in major orthopaedic surgery. J Am Acad Orthop Surg 2010;18:132-138.
41. Okamoto S, Nakajima T, Okamoto U, et al. A suppressing effect of e-amino-n-caproic acid on the bleeding of dogs, produced with the activation of plasmin in the circulatory blood. Keio J Med 1959;8:247-266.
42. Belko JS, Warren R, Regan EE, et al. Induced fibrinolytic activity and hypofibrinogenemia - effect of epsilon-amino-caproic acid. Arch Surg 1963;86:396-401.
43. Okamoto S, Oshiba S, Mihara H, et al. Synthetic inhibitors of fibrinolysis - in vitro and in vivo mode of action. Ann N Y Acad Sci 1968;146(A2):414-429.
44. Hoylaerts M, Lijnen HR, Collen D. Studies on the mechanism of the antifibrinolytic action of tranexamic acid. Biochim Biophys Acta 1981;673:75-85.
45. Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI) - how does thrombin regulate fibrinolysis? Ann Med 2006;38:378-388.
46. Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007:CD001886.
47. Cliffton EE. I. Evidence that a hypercoagulable state precedes massive oozing during and after major surgery. 2. Effect of epsilon-aminocaproic acid (EACA) in control of surgical oozing. Bibl Haematol 1965; (23P5):1264-1277.
48. Jordan D, Delphin E, Rose E. Prophylactic epsilon-aminocaproic acid (EACA) administration minimizes blood replacement therapy during cardiac-surgery. Anesth Analg 1995;80:827-829.
49. Pokorny F. Toxicological experiments with cyclohexamine oxine, e caprolactein and e aminocaproic acid. Mutual biological comparison. Sb Lek 1952;54:28.
50. Lang K, Bitz H. Metabolism of e aminocaproic acid. Biochem Z 1954;324(7):495-498.
51. Polizopoulou ZS, Koutinas AF, Patsikas MN, Soubasis N. Evaluation of a proposed therapeutic protocol in 12 dogs with tentative degenerative myelopathy. Acta Vet Hung 2008;56:293-301.
52. Regnier A, Cazalot G, Cantaloube B. Topical treatment of non-healing corneal epithelial ulcers in dogs with aminocaproic acid. Vet Rec 2005;157:510-513.
53. Rosenberger JA, Pablo NV, Crawford PC. Prevalence of and intrinsic risk factors for appendicular osteosarcorna in dogs: 179 cases (1996-2005). JAVMAn 2007;231:1076-1080.
54. Mihu D, Costin N, Mihu C, et al. HELLP syndrome-a multisystemic disorder. J Gastrointest Liver Dis 2007;16:419-424.
55. Hoffman M, Monroe DM. Coagulation 2006: a modern view of hemostasis. Hematol Oncol Clin North Am 2007;21:1-11.
56. Kraft P, Schwarz T, Meijers JCM, et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke. Plos One 2010;19;5(7):e11658.